Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Further Major Agreement Signed in the US

28 Jun 2016 07:00

RNS Number : 4458C
Premier Veterinary Group PLC
28 June 2016
 

 

 

 

PREMIER VETERINARY GROUP PLC

("PVG" or "the Company")

 

 

FURTHER MAJOR AGREEMENT SIGNED IN THE US FOR PREMIER PET CARE PLAN

 

UPDATE ON PREMIER PET CARE PLAN GROWTH

London, UK, 28 June 2016 - Premier Veterinary Group plc (LSE: PVG) announces that its wholly-owned subsidiary, Premier Vet Alliance (US) Limited ("PVA"), has signed another major agreement in the US for its preventative healthcare program for pets, branded as Premier Pet Care Plan ("PPCP").

The latest agreement has been entered into with Merritt Veterinary Supplies Inc. ("MVS"), a leading veterinary supplies distributor founded in 1938, which has 9,000 member hospitals in the south east of the US. MVS is headquartered in Columbia, South Carolina.

The initial 5-year agreement, as exclusive preferred provider of preventative healthcare programs, is to introduce PPCP to MVS' member hospitals, located primarily in South Carolina, North Carolina, Georgia, Alabama, Florida, Mississippi, Louisiana, Tennessee, Kentucky and Indiana. Recruitment of the product launch and training team has already commenced to service this substantial account, and this will be supported by MVS' internal 42-strong sales team. The first pets on plan from this agreement are expected during the second half of the current calendar year.

 

Bobby Mins, President of MVS, commented:

"I see the Premier Pet Care Plan as a great opportunity for Merritt as a Distributor as this will significantly improve compliance rates on the key healthcare products with a consequent increase in sales."

Dominic Tonner, Chief Executive Officer of PVG, added:

"I am delighted to announce this deal with one of the oldest and most respected distributors in the Southeastern United States. The agreement will very significantly enhance growth and market share. Bobby's team have totally embraced our proposition and we look forward to working with them closely to improve the clinic performance of their customer base."

 

Premier Pet Care Plan Customer Growth

The number of pets on active plans in the third quarter of 2016, and in the preceding three quarters, are as follows:

 

 

As at

As at

As at

As at

 

Sep-15

Dec-15

Mar-16

Jun-16

Rest of World

3,000

5,000

10,000

14,000

United Kingdom

79,000

99,000

107,000

115,000

 

Total no of pets on plan

82,000

104,000

117,000

129,000

 

For further information, please contact:

 

Premier Veterinary Group plc Tel: +44 (0)117 970 4130

Dominic Tonner, Chief Executive Officer

Daniel Smith, Chief Financial Officer

 

Square1 Consulting Tel: +44 (0)207 929 5599

David Bick/Brian Alexander

 

 

Note to Editors:

 

The available market for preventative healthcare programs for pets across the US is estimated at 70 million dogs and 74 million cats (U.S. Pet Ownership & Demographics Sourcebook 2012).

PVG's services to third party veterinary practices, through its wholly-owned subsidiary Premier Vet Alliance Limited ("PVA"), include the administration and support of a preventative healthcare program for pets branded "Premier Pet Care Plan" ("PPCP"); and the operation of a buying group (the "PVA Buying Group") which offers enhanced discounts to member practices on pharmaceutical and consumable spending. In the US, Premier Pet Care Plan is marketed through the Company's wholly-owned subsidiary, Premier Vet Alliance (US) Limited.

 

PPCP is a structured, preventative healthcare program for cats, dogs and rabbits and is available only through veterinary practices. The program is seen as a way of providing gold standard care for pets at an affordable price for the client, by way of fixed monthly payments.

 

 

 

 

 

PPCP uses a clinical approach to prevention, as this is the most effective method of ensuring illnesses are diagnosed more quickly and not given a chance to advance. What truly sets PPCP apart is its unique approach of offering an end-to-end solution and support to the practice, which has been proven to work extremely well. PVA works alongside practices to create a tailor-made, cost-effective service for clients, one that delivers excellent care to their patients and significantly improves practice performance.

 

The PVA Buying Group, is now the UK's largest veterinary buying group without group interests in veterinary practices or veterinary wholesalers offering its members the best discounts across the industry on pharmaceutical and consumable spend.

 

For further details:

 

http://www.premiervetalliance.co.uk/;

 

http://www.merrittvet.com/home.aspx

 

 

This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for future operations, and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. These forward-looking statements speak only as at the date of this announcement. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, readers are cautioned not to rely on any forward-looking statement.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRPGUAWQUPQUAR
Date   Source Headline
14th Jun 201011:45 amRNSForm 8.5 (EPT/RI)
14th Jun 20109:16 amRNSForm 8.5 (EPT/NON-RI)
11th Jun 20102:06 pmRNSForm 8.3 - Ark Therapeutics Group PLC
11th Jun 201012:46 pmRNSForm 8.3 - Ark Therapeutics Plc
11th Jun 201010:16 amRNSForm 8.5 (EPT/RI)
11th Jun 20109:52 amRNSForm 8.5 (EPT/NON-RI)
10th Jun 201010:17 amRNSForm 8.5 (EPT/NON-RI)
10th Jun 201010:13 amRNSForm 8.5 (EPT/RI)
9th Jun 201011:38 amRNSForm 8.5 (EPT/RI)
9th Jun 201010:08 amRNSForm 8.5 (EPT/NON-RI)
8th Jun 20104:40 pmRNSSecond Price Monitoring Extn
8th Jun 20104:35 pmRNSPrice Monitoring Extension
8th Jun 201012:36 pmRNSForm 8.3 - Ark Therapeutics
8th Jun 201011:15 amRNSForm 8.5 (EPT/NON-RI)
8th Jun 201011:11 amRNSForm 8.5 (EPT/RI)
7th Jun 20102:53 pmRNSForm 8.3 - Ark Therapeutics Group PLC
7th Jun 201011:55 amRNSForm 8.3 - [Ark Therapeutics Group plc]
7th Jun 201011:04 amRNSForm 8.5 (EPT/RI)-Amendment
7th Jun 201011:04 amRNSForm 8.5 (EPT/RI)
7th Jun 20109:41 amRNSForm 8.5 (EPT/NON-RI)
4th Jun 201012:43 pmRNSForm 8.3 - ARK THERAPEUTICS
4th Jun 201011:43 amRNSForm 8.5 (EPT/RI)
4th Jun 201010:25 amRNSForm 8.5 (EPT/NON-RI)
3rd Jun 20102:53 pmRNSForm 8.3 - Ark Therapeutics Group PLC
3rd Jun 201011:37 amRNSForm 8.5 (EPT/RI)
3rd Jun 201011:25 amRNSForm 8.5 (EPT/NON-RI)
3rd Jun 201010:28 amRNSBlocklisting Interim Review
2nd Jun 20103:07 pmRNSForm 8.3 - Ark Therapeutics Group PLC
2nd Jun 201011:38 amRNSForm 8.5 (EPT/RI)
2nd Jun 20109:22 amRNSForm 8.5 (EPT/NON-RI)
1st Jun 20102:47 pmRNSForm 8.3 - Ark Therapeutics Group PLC
1st Jun 20102:45 pmRNSForm 8.3 - Ark Therapeutics
1st Jun 201010:08 amRNSForm 8.5 (EPT/NON-RI)
28th May 201011:08 amRNSForm 8.5 (EPT/NON-RI)
27th May 20103:17 pmRNSForm 8.3 - Ark Therapeutics Group PLC
27th May 201010:41 amRNSForm 8.5 (EPT/RI)
27th May 20109:04 amRNSForm 8.5 (EPT/NON-RI)
26th May 201011:45 amRNSForm 8.5 (EPT/NON-RI)
25th May 20104:40 pmRNSSecond Price Monitoring Extn
25th May 20104:35 pmRNSPrice Monitoring Extension
25th May 201010:44 amRNSForm 8.5 (EPT/NON-RI)
24th May 20109:10 amRNSForm 8.5 (EPT/NON-RI)
24th May 20107:00 amRNSAppointment of CFO and Company Secretary
21st May 20103:32 pmRNSForm 8.5 (EPT/RI)
21st May 20109:55 amRNSForm 8.5 (EPT/NON-RI)
20th May 20109:50 amRNSForm 8.5 (EPT/NON-RI)
19th May 201010:48 amRNSForm 8.5 (EPT/NON-RI)
18th May 201011:05 amRNSForm 8.5 (EPT/NON-RI)
18th May 201010:11 amRNSForm 8.5 (EPT/RI)
18th May 20107:00 amRNSInterim Management Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.